property Rights


That any pharma product has successfully undergo the regulatory affairs scanners before launched within the market need less to say . Biosimilars and biologics are not any exceptions. the businesses developing these biosimilars and biologics aside from regulatory aspects tend to enjoy monopoly over their product. property Rights (IPR) and patents are ultimate tools to the biosimilar manufacturers for safeguarding their interests. 2016 was a record year for development of Biosimilars & biologics in US. during this year 16 IPR petition was filed. So, expected scenario of 2017 would be a boom in Biosimilar and biologics field.


  • The Budapest Treaty
  • The Patent Act and biological innovations
  • TRIPS negotiations on biotechnology

Related Conference of property Rights

April 14-15, 2025

18th European Biosimilars Congress

Paris, France
April 14-15, 2025

35th Annual European Pharma Congress

Paris, France
April 24-25, 2025

18th World Drug Delivery Summit

London, UK
May 05-06, 2025

19th World Drug Delivery Summit

Vancouver, Canada
June 16-17, 2025

3rd Global Online Summit on Nanoscience and Nanotechnology

Zurich, Switzerland
June 23-24, 2025

38th World Congress on Pharmacology

Paris, France
August 18-19, 2025

40th World Congress on Pharmacology and Therapeutics

Valencia, Spain
September 22-23, 2025

Pharma Biotech Expo

Toronto, Canada
September 23-24, 2025

10th International Conference on Future Pharma and Innovations

Amsterdam, Netherlands
November 27-28, 2025

4th World Congress on Precision and Personalized Medicine

Zurich, Switzerland
November 27-28, 2025

4th World Conference on Pharma Industry and Medical Devices

Zurich, Switzerland
November 27-28, 2025

13th International Conference on Clinical Trials

Amsterdam, Netherlands

property Rights Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in